SJB is supported by training grant T32 CA009314 from the National Cancer Institute, National Institutes of Health and received financial support from the training grant to attend the American Society of Preventive Oncology conference. PDB serves as an emerging medical advisory board member for the Hepatitis B Foundation (unpaid) and as a committee member on the American Association for the Study of Liver Diseases Special Interest Group for hepatitis B virus (unpaid) and has received a travel award from the Chronic Liver Disease Foundation to attend the Liver Connect Conference. MS serves on the scientific advisory board related to hepatitis B investigational therapeutics and hepatitis C virus elimination for Aligos, Arbutus, AbbVie, Gilead, GSK, Pfizer, Precision Biosciences, Vir Biotechnology, and Virion; is on the data safety monitoring board for HIV clinical trials with Gilead; and has given expert testimony for the United States Attorney's Office, Department of Justice. SW received research funding (to institution) from Gilead Sciences; honorarium (to institution) from PRIME and Peer Review; received travel and accommodation from WHO and the Hepatitis B Foundation; and serves on the board of directors for the Hepatitis B Foundation (unpaid). TT received a Paul & Valeria Ainsworth Fellowship; has received research funds (to institution) from Gilead Sciences for research and community development projects, ACH4 project grants, a GESA project grant, a NHMRC project grant, and a project grant from the Stephan Urban Foundation; serves as a consultant to Excision BioTherapeutics and Kerna Ventures (to institution), is a paid consultant to Gilead Sciences and GSK; received payment for speaking engagements from GSK, the Australasian Society for HIV, and the Singapore HBV Cure conference; and received travel and accommodation funds from GSK and the Singapore HBV Cure conference. CC received education and research grants (to institution) from Gilead Sciences, GSK, Vir Biotechnology, Dynavax Technologies, and Roche; and serves on patient and advocacy advisory councils for GSK and Gilead Sciences (renumeration to Hepatitis B Foundation). CSG declares no competing interests. This work is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.